Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25880382 | 0.92 | HSD17B10 (0.36) | HSD17B10HPGDKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL25880354 | 0.90 | HSD17B10 (0.41) | HSD17B10HPGDKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL25880425 | 0.89 | NR3C1 (0.35) | HSD17B10HSP90AA1GLO1L3MBTL1MAPT | |
| SCHEMBL20857876 | 0.86 | HSD17B10 (0.35) | HSD17B10HSP90AA1L3MBTL1 | |
| SCHEMBL25880383 | 0.86 | HSD17B10 (0.35) | HSD17B10HPGDKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL21262984 | 0.83 | HSD17B10 (0.35) | HSD17B10HSP90AA1HPGDKDM4EALDH1A1 | |
| SCHEMBL25880422 | 0.83 | ALK (0.35) | L3MBTL1MAPTNR3C1 | |
| SCHEMBL25880370 | 0.83 | BRD9 (0.42) | HSD17B10HPGDKDM4EALDH1A1MAPT | |
| SCHEMBL25880375 | 0.82 | HSD17B10 (0.38) | HSD17B10HPGDKDM4EALDH1A1MAPT | |
| SCHEMBL21126985 | 0.81 | HSD17B10 (0.31) | HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230240135-A1 | HETEROCYLIC COMPOUND, LIGHT-EMITTING DEVICE INCLUDING THE HETEROCYCLIC COMPOUND AND ELECTRONIC APPARATUS INCLUDING THE LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-07-27 | — | — | US | disclosed |
| US-20230240135-A1 | HETEROCYLIC COMPOUND, LIGHT-EMITTING DEVICE INCLUDING THE HETEROCYCLIC COMPOUND AND ELECTRONIC APPARATUS INCLUDING THE LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230240135-A1 | HETEROCYLIC COMPOUND, LIGHT-EMITTING DEVICE INCLUDING THE HETEROCYCLIC COMPOUND AND ELECTRONIC APPARATUS INCLUDING THE LIGHT-EMITTING DEVICE | CRY1, LAGE3, NQO1 | HSD17B10 1229/4885HSP90AA1 3975/4885HPGD 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.